文献リスト

1) Novel swine-origin influenza A (H1N1) virus investigation team. Emergence of novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009; 360: 2605-15

2) Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009; 360: 2616-25

3) World Health Organization. H1N1 in post-pandemic period. Director-General's opening statement at virtual press conference. 10 August 2010. http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html

4) 岡部信彦, パンデミックインフルエンザ対策チーム. パンデミック(H1N1)2009発生から1年を経て. 病原微生物検出情報. 2010; 31: 250-1. (http://idsc.nih.go.jp/iasr/31/367/dj3671.html)

5) World Health Organization. Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Weekly Epidemiological Record. 2009; 84: 481-4

6) Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009; 361: 2507-17

7) Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009; 302: 1896-902

8) 厚生労働省新型インフルエンザ対策推進本部. 今般の新型インフルエンザ(H1N1)対策について～対策の総括のために～平成22年3月31日インフルエンザ対策総括会議資料. 厚生労働省. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/dl/infu100331-02.pdf

9) 社団法人日本感染症学会新型インフルエンザ対策委員会. 2010年の総括と2010 / 2011冬に向けた日本感染症学会の考え方. http://www.kansensho.or.jp/influenza/pdf/101202_thinking.pdf

10) Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361: 1935-44

11) Moscona A. Neuraminidase inhibitors for Influenza. N Engl J Med. 2005; 353: 1363-73

12) Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systemic review and meta-analysis. BMJ. 2009; 339: b5106, doi: 10. 1136/bmj. b5106

13) Donaldson LJ, Rutter PD, Ellis BM, et al. Mortality from pandemic A/H1N1 2009 influenza in England: Public health surveillance study. BMJ. 2009; 339: b5213, doi: 10. 1136/bmj. b5213

14) Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009; 302: 1880-7

15) Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmaco- kinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010; 182: 357-63

16) Slopen ME, Mosquera MC, Balter S, et al. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. Morb Mortal Wkly Rep. 2010; 58: 1436-40

17) Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010; 362: 27-35

18) Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009; 374: 451-8

19) Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect. 2010; 60: 257-63

20) Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza, recommendations of the advisory committee on immunization practice (ACIP), 2008. Morb Mortal Wkly Rep. 2008; 57 (RR07): 1-60

21) Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the infectious diseases society of America. CID 2009; 48: 1003-32

22) Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza, recommendations of the advisory committee on immunization practice (ACIP). Morb Mortal Wkly Rep. 2011; 60 (RR01): 1-25

23) Writing Committee of the WHO consultation on clinical aspects of pandemic (H1N1) 2009 influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010; 362: 1708-19

24) 医薬品インタビューフォーム. リレンザ®ザナミビル水和物ドライパウダーインヘラー. 2009年11月(改訂第9版)

25) 医薬品インタビューフォーム. タミフル®カプセル75, タミフル®ドライシロップ3%, オセルタミビルリン酸塩製剤. 2010年7月(改訂24版)

26) Tullu MS. Oseltamivir. Journal of Postgraduate Medicine. 2009; 55: 225-30

27) 厚生労働省, 薬事・食品衛生審議会, 医薬品等安全対策部会, 安全対策調査会. リン酸オセルタミビル(タミフル)について. http://www.mhlw.go.jp/shingi/2009/06/s0616-5.html

28) Izumi Y, Tokuda K, O'Dell KA, et al. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neuroscience Letters. 2007; 426, 54-8

29) Webster D, Li Y, Bastien N, et al. Oseltamivir- resistant pandemic H1N1 influenza. CMAJ. 2011; 183: E420-2

30) 医薬品インタビューフォーム. ラピアクタ®点滴用バッグ300mg, ラピアクタ®点滴用バイアル150mg. 2011年6月(第4版)

31) Mancuso CE, Gabay MP, Steinke LM, et al. Peramivir: An intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother. 2010; 44: 1240-9

32) Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010; 54: 4568-74

33) Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006; 69: 39-45

34) Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes surbibal in ferrets and mice infected with highly virulent influenza virus A/Vietnam/1203/04(H5N1). Virology. 2008; 374: 198-209

35) Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. CID. 2011; 52: 695-706

36) Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 2007; 74: 159-62

37) 高下恵美, 江島美穂, 藤崎誠一郎, 他. ペラミビル治療患者からのH275Y耐性ウイルス検出事例報告(掲載日2011/2/18). 病原微生物検出情報(IASR), 国立感染症研究所. http://idsc.nih.go.jp/iasr/rapid/pr3732.html

38) 医薬品インタビューフォーム. イナビル®吸入粉末剤20mg. 2011年6月(第4版)

39) Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010; 54: 1256-64

40) Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010; 54: 2575-82

41) Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009; 53: 186-92

42) Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol. 2010; 50: 1319-29

43) Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neruraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009; 53: 4845-51

44) Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor Laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. CID. 2010; 51: 1167-75

45) Kiso M, Kubo S, Ozawa M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathogens. 2010; 6: 1-10

46) Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460: 1021-5

47) Furuta Y, Takahashi K, Shiraki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49: 981-6

48) Furuta Y, Takahashi K, Shiraki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46: 977-81

49) Takahashi K, Furuta Y, Shiraki K, et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antimicrob Agents Chemother. 2003; 14: 235-41

50) Sleeman K, Mishin VP, Deyde VM, et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viru-ses. Antimicrob Agents Chemother. 2010; 54: 2517-24

51) Kiso M, Takahashi K, Tagawa YS, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. PNAS. 2010; 107: 882-7

52) Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007; 51: 845-51

53) Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza a virus infections in mice. Antimicrob Agents Chemother. 2010; 54: 126-33

54) Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009; 82: 95-102

55) Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: Analytic strategy using propensity scores. Am J Respir Crit. Care Med. 2011; 183: 1207-14

56) Buisson CB, Richard JCM, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011; 183: 1200-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp